Incyte's Monjuvi combined with Bristol Myers Squibb's Revlimid and R-CHOP reduced the risk of disease progression, relapse or death by 25% compared to R-CHOP alone in approximately 900 patients with newly diagnosed diffuse large B-cell lymphoma. Trial data first announced in January 2026 was presented at the American Society of Clinical Oncology meeting on May 30, 2026. Severe adverse events occurred in 87% of Monjuvi combo patients versus 76% receiving R-CHOP alone.
Monjuvi trial results
- ▪The Monjuvi trial tested a combination of Monjuvi, Bristol Myers Squibb's Revlimid and R-CHOP against R-CHOP alone in approximately 900 patients with newly diagnosed diffuse large B-cell lymphoma
- ▪The detailed Monjuvi trial results were presented at the American Society of Clinical Oncology meeting in Chicago on May 30, 2026
- ▪Incyte first announced the Monjuvi trial data in January 2026
- ▪The overall death rate for the Incyte/Bristol Myers/R-CHOP combination was 18.5%, compared to 21.7% for R-CHOP alone
- ▪Incyte's Monjuvi as part of a multi-drug regimen reduced the risk of disease progression, relapse or death by 25% compared to the standard alone in a trial for diffuse large B-cell lymphoma
Safety profile comparison
- ▪Severe adverse events occurred in nearly 87% of patients who received the Monjuvi combo versus 76% of patients who received R-CHOP alone
- ▪Discontinuations due to treatment-related adverse events were 25.7% for the Monjuvi combo, compared with 18% for R-CHOP standard care
Regulatory expansion plans
- ▪Monjuvi received accelerated U.S. approval in combination with Revlimid for patients whose diffuse large B-cell lymphoma has returned or did not respond to earlier treatment, and those who are not eligible for stem cell transplant
- ▪Incyte plans to seek expanded approval in the U.S. and Europe for the Monjuvi combo therapy as an initial treatment for newly diagnosed diffuse large B-cell lymphoma patients
Market opportunity
- ▪About 18,000 to 25,000 people in the U.S. are diagnosed with diffuse large B-cell lymphoma each year
- ▪Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma
- ▪More than 50% of the high-risk diffuse large B-cell lymphoma patient population that still receives R-CHOP as treatment could be eligible for the Monjuvi regimen as a first-line therapy
Story comments
Loading comments…